Background: Previous studies have identified sub-clinical inflammation as a potential factor in the pathogenesis of cancer and cardiovascular disease (CVD) but the possibility that simple, readily measured indices of sub-clinical inflammation might predict both CVD and cancer has not been tested in the context of a single, prospective analysis. Aim: To evaluate simply measured indices of inflammation as long-term predictors of death from either cancer or CVD.
Summary
Background: Previous studies have identified sub-clinical inflammation as a potential factor in the pathogenesis of cancer and cardiovascular disease (CVD) but the possibility that simple, readily measured indices of sub-clinical inflammation might predict both CVD and cancer has not been tested in the context of a single, prospective analysis. Aim: To evaluate simply measured indices of inflammation as long-term predictors of death from either cancer or CVD.
Design: Prospective open cohort study. Methods: A total of 1192 white males received measurements of a range of risk markers including the inflammation indices white blood cell count (WBC), erythrocyte sedimentation rate (ESR) and serum globulin concentrations. Inflammation marker clustering was quantified as a factor-analysis-derived inflammation score and survival time to death from any cancer or CVD was modeled on baseline measures using the Cox proportional hazards model.
Results:
A total of 1010 participants met inclusion criteria, of whom 94 died of cancer and 67 of CVD. Mean follow-up times among cases and survivors ranged from 18.2-21.9 years. Independently of established risk factors [age, body mass index (BMI), smoking, alcohol and exercise], WBC, ESR and globulin levels were all individually predictive of both cancer (hazard ratio 1.43, P = 0.002; 1.27, P = 0.02; 1.26, P = 0.02, respectively) and CVD mortality (1.29, P = 0.06; 1.43, P = 0.007; 1.50, P = 0.001). The inflammation score predicted both cancer mortality (1.35, P = 0.003) and CVD mortality (1.46, P = 0.002). Risks associated with high inflammation score were equivalent to and independent of smoking cigarettes for cancer or, for CVD, having a serum cholesterol concentration !6.2 mmol/l. Conclusions: Simple indices of inflammation predict death from cancer or CVD two decades later as strongly as smoking predicts cancer or cholesterol predicts CVD. Their measurement could contribute to evaluation of both cancer and CVD risk.
Introduction
The importance of sub-clinical inflammation in atherogenesis is widely acknowledged 1 and a role for inflammation in carcinogenesis is increasingly recognized. [2] [3] Many studies have identified plasma inflammation markers, such as C-reactive protein (CRP), 4 fibrinogen, 5 white blood-cell count (WBC), low-serum albumin concentrations 6 and erythrocyte sedimentation rate (ESR) [7] [8] as predictors of incident cardiovascular disease (CVD) but, with the exception of CRP and WBC, there are appreciably fewer studies of these markers as predictors of cancer. [9] [10] [11] [12] [13] [14] Prediction of both CVD and cancer by WBC was reported some years ago 11 and by CRP in recent meta-analysis. 4 Otherwise, studies have simply distinguished cardiovascular and non-cardiovascular events. 15, 16 The possibility that sub-clinical inflammation might predict both CVD and cancer does not appear to have been formally tested in a single, prospective analysis. Consequently, little is known of its relative importance in the development of CVD and cancer in specific populations, or of the durations over which such associations might act, or whether measurement of inflammation markers might help in the evaluation of risk of both diseases.
The Heart Disease and Diabetes Risk Indicators in a Screened Cohort (HDDRISC) Study incorporates a long follow-up, measurement of a range of inflammatory and CVD risk biomarkers and almost complete mortality ascertainment. We, therefore, explored prediction of death from CVD, cancer and other causes by established biomarkers for CVD risk, readily measured individual inflammation markers and a composite measure of inflammation status.
Materials and methods

Participants
The HDDRISC Study was established as an open cohort study of predictors of CVD and diabetes. The study began in 1971 as a company health screening program, in the course of which participants received a range of metabolic, clinical and laboratory measurements. There were 1278 participants recruited of whom 1192 were white males and make up the HDDRISC cohort. The study received local ethics committee approval (Wynn Institute and St Mary's Hospital Research Ethics Committees) and each participant gave their written informed consent.
Procedures and measurements
Procedures and measurements have been described previously. 17 In brief, participants were instructed to have fasted overnight (>12 h), to have taken only water and refrained from cigarette smoking. Height and weight were measured and a clinical history taken, including details of smoking and alcohol consumption and exercise habits. Participants rested for 15 min, systolic and diastolic blood pressures (BPs) were measured using a mercury sphygmomanometer, then blood samples were taken for measurement of indices of liver function (including serum globulin, derived as the difference between total protein and albumin), hematology (including WBC) and lipid and carbohydrate metabolism. From 1978 onwards, serum high-density lipoprotein (HDL) cholesterol concentration was also measured. ESR was measured by the Westergren method. Routine laboratory measurements were made using standard methodology. Serum cholesterol, triglycerides, HDL and low-density lipoprotein (LDL) cholesterol concentrations were measured in our own laboratories as described previously 17 Cancer and CVD mortality ascertainment Deaths in the UK till 1 January 2010 were identified through the NHS Information Centre for Health and Social Care. Deaths overseas were notified by family members of the deceased and by the company for which the health screening program was undertaken. Death from cancer was assigned if any kind of cancer was listed as the primary cause of death on the death certificate and defined as a potentially fatal or metastatic, non-benign tumor. In the event of ambiguity, advice from a pathologist was sought. Death from CVD was assigned if myocardial infarction, coronary artery disease or thrombosis, cerebrovascular incident, stroke, peripheral vascular disease or aortic aneurysm was recorded as a primary cause of death. Deaths from causes other than cancer or CVD were classified as 'other deaths'. Follow-up time was calculated as the time between baseline visit and death or, for those still alive, between baseline visit and 1 January 2010. With the exception of 27 individuals who are no longer traceable, mortality ascertainment for the HDDRISC cohort is complete.
Data analysis
Participants with a clinical history of cancer or CVD at their baseline visit were excluded from the analysis as were those known to have developed cancer or CVD subsequently but who were still alive on 1 January 2010. Some included among the survivors will, nevertheless, have developed cancer or CVD since, in contrast to mortality, ascertainment of incident cancer and CVD in the HDDRISC study has not been systematically undertaken. The presence of these participants would be expected to favor false-negative rather than false-positive findings.
Statistical analyses were performed using STATA 8 (Stata, College Station, Texas, USA). Smoking, alcohol consumption and physical activity were coded as previously described. 17 Body mass index (BMI) was calculated as weight (kg)/height (metres) 2 . The HDL-non-HDL cholesterol ratio was derived as HDL cholesterol/(total cholesterol À HDL cholesterol). Fasting plasma glucose (FPG) was taken as the mean of two fasting measurements. Measured variables were assessed for the normality of their distributions according to the skewness and kurtosis and the joint statistic for departures from normality provided by STATA command, 'sktest'. Baseline summary statistics for those who did and did not die of cancer, CVD or other causes were derived as means and standard deviations for normally distributed variables, medians and inter-quartile ranges for non-normally distributed variables and percentages for categorical variables.
The factor score from a factor analysis (STATA command 'factor') of the four inter-correlated indices of sub-clinical inflammation, WBC, ESR, globulin and albumin, was used to derive a single inflammation score. Factor analysis, as used previously to characterize insulin resistance-related risk-factor clustering in this cohort, 18 identifies underlying 'factors' responsible for co-associations between inter-correlated variables. Each variable entered in a factor analysis is associated with a given factor according to a 'loading', which quantifies the importance of that variable as a feature of the factor. For a given individual, summing the products of the individual's value for each variable (standardized according to its mean and standard deviation) and the loading of each variable on a particular factor provides a score for that factor for the individual. This 'factor score' quantifies the intensity with which the cluster of co-associated variables is expressed in the individual and can be used as a single variable in further statistical analysis. We expected the four indices of sub-clinical inflammation to appear as features of a single factor. The analysis was, therefore, confirmatory. 19 Cox proportional hazards modeling was used to determine whether a variable significantly influenced time to death from cancer, CVD or other causes. Variables were entered into the Cox model as standardized values to assist interpretation of their relative importance. The proportionality assumption was tested by the Schoenfeld test. The approach of Kay was adopted 20 whereby deaths from causes other than the cause of interest were regarded as competing risks, with censoring to the time of death. This enables the biological effect of independent variables entered in the Cox model to be evaluated specifically with respect to the cause of death of interest. 21 In an alternative approach, effects of competing risks were accounted for using the data augmentation approach of Lunn and McNeil. 22 This enables the relationship between independent variables and cause-specific death to be evaluated with competing causes of death incorporated into the model as indicator variables.
Since the potential predictors of death were selected on the basis of established evidence, the universal null hypothesis did not apply and correction of the level of statistical significance for multiple testing was not appropriate. 23 Nevertheless, for selection of predictors for further analysis, we chose a significance level of <0.01 since individual variables that predicted at lower levels of significance were unlikely to be important.
Results
Of the 1192 participants in the HDDRISC study, 1104 had complete data for relevant variables. Of these, 19 had been lost to follow-up and 19 had evidence of existing CVD or cancer. Of the remaining 1066, 28 were known to have developed evidence of cancer and 28 evidence of CVD after their baseline visit but were still alive on 1 January 2010. The analysis then concerned the remaining 1010. Of these, 94 died of cancer, 67 of CVD and 57 of other causes. WBC, ESR globulin and albumin were all inter-correlated at P < 0.001. Factor analysis of these four variables returned a single factor with factor loadings for WBC, ESR globulin and albumin of 0.34, 0.39, 0.70 and À0.63, respectively. For each participant, the inflammation factor score was then given by:
Mean ages at baseline in the three groups of participants who died ranged from 52.2 to 52.7 years (analysis of variance: ANOVA P = 0.9). However, the mean age at baseline of the 792 survivors was 44.3 years (ANOVA P < 0.001). There were insufficient survivors aged >65 years at baseline to enable matching for age and it was decided to limit the survivor group to the 374 aged >45 years at baseline. The median age of the survivors was then 50.3 years and median ages among those who died from cancer, CVD or from other causes ranged from 52.2 to 53.0 years (ANOVA P = 0.003). Numbers of participants dying from specific cancers are shown in Table 1 . With regard to CVD, 47 died from coronary heart disease, 19 from cerebrovascular disease and one from aortic aneurysm. Deaths from other causes were primarily from infection, respiratory disease, pneumonia and accident. Baseline characteristics of each group are shown in Table  2 . At baseline, a single participant was taking lipid-lowering therapy (a statin), 14 BP-lowering therapy, two glucose-lowering therapy and 13 had a FPG of 7.0 mmol/l or more. Mean time from baseline to death ranged from 18.2 years (cancer) to 21.9 years (other deaths). Mean follow-up among the survivors was 21.6 years.
In univariate Cox proportional hazards analysis (Table 3 ), significant predictors (P < 0.05) of survival time to death from cancer were: age, current smoking (!15 cigarettes per day), an alcohol intake of !28 units per week, WBC, ESR, globulin, albumin, the inflammation factor score, the HDL-non-HDL cholesterol ratio and systolic BP. BMI and diastolic BP predicted at borderline significance (both P = 0.05). Significant predictors of survival time to death from CVD were: age, current smoking (<15 cigarettes per day), WBC, ESR, globulin, the inflammation factor score, total, LDL and HDL cholesterol, triglycerides, the HDL-non-HDL cholesterol ratio, systolic and diastolic BP and FPG. None of the variables considered predicted survival time to death from other causes.
Significant univariate predictors of survival time (P < 0.01) were evaluated in multivariable Cox proportional hazard models to explore their independence from age, BMI, cigarette smoking and alcohol intake ( Table 4) . Independent predictors of cancer were WBC (P = 0.002), the inflammation factor score (P = 0.003) and ESR and globulin (both P = 0.02). Independent predictors of death from CVD were globulin (P = 0.001), the inflammation factor score (P = 0.002) and ESR (P = 0.007). Other predictors of death from CVD were total and LDL cholesterol and systolic and diastolic BP (all P < 0.01) and FPG (P < 0.05). The greatest effect of a 1 SD change in any variable was seen for WBC for cancer [hazard ratio (HR: 1.43)] and for globulin for AVD (HR: 1.50).
In models incorporating age, BMI, cigarette smoking and alcohol intake, with effects of competing risks taken into account using the data augmentation approach, findings were very similar. Independent predictors of death from cancer were WBC (HR 1.41, P = 0.009) and inflammation score (HR 1.29, P = 0.009). Independent predictors of death from CVD were WBC (HR 1.30, P = 0.03), ESR (HR 1.44, P = 0.004), globulin (HR 1.50, P < 0.001), the inflammation score (HR 1.45, P = 0.001), cholesterol (HR 1.46, P = 0.001), LDL cholesterol (HR 1.41, P = 0.004), triglycerides (HR 1.30, P = 0.04), the HDL-non-HDL cholesterol ratio (HR 0.63, P = 0.004), systolic BP (HR 1.33, P = 0.002), diastolic BP (HR 1.42, P = 0.005) and FPG (HR 1.10, P = 0.009). Again, none of these variables were significant predictors of death from other causes.
The inflammation score was explored relative to categories of the established risk factors, current smoking for cancer and serum cholesterol >6.2 mmol/l for CVD. Thirty-six percent of participants were current smokers (HR 1.63, P = 0.01). When the 36% of participants with the highest inflammation scores (score >0.31) were categorized and entered in a bivariable model with current smoking, the hazard ratio for high-inflammation score was 1.87 (P = 0.005) and for smoking 1.47 (P = 0.06). Twenty-seven percent of participants had a serum cholesterol concentration !6.2 mmol/l (HR 1.99, P = 0.005). When the 27% of participants with the highest values for the inflammation score (score >0.56) were categorized and entered in bivariable Cox proportional hazards models with cholesterol !6.2 mmol/l, the hazard ratio for high cholesterol was 1.96 (P = 0.007) and for the inflammation score 2.10 (P < 0.005). 
Discussion
Readily measured markers of sub-clinical inflammation, evaluated 18-20 years prior to death, predicted whether an individual was at risk of dying from cancer or CVD. Death from CVD, but not cancer, was also predicted by lipid and BP measures. Inflammation was as important as cigarette smoking for death from cancer and cholesterol for death from CVD, but death from causes other than cancer or CVD was not predicted by any of the variables we considered. These findings strongly support the possibility that sub-clinical inflammation provides a common ground in which either cancer or atherosclerosis can develop, analogous to the 'common soil' from which atherosclerosis or diabetes can emerge. 24 Our study has limitations and strengths, its principal strengths being the measurement of a broad range of risk markers, the long duration of follow-up and relatively low exposure to drug interventions such as statin therapy. The main limitations were the relatively small sample size and number of outcomes, which precluded an adequately powered analysis of particular types of cancer or CVD. Our study was also restricted to mortality outcomes, which leaves open the possibility that sub-clinical disease might have been present at the time baseline measurements were made and might, therefore, have biased our findings in favor of a positive relationship between biomarker levels and mortality. It might be expected that sub-clinical disease would be present closer to the time of death from cancer and that measurements made closer to time of death would be more likely to be affected by sub-clinical disease. If sub-clinical disease was affecting biomarker levels in this way, a relationship might then be expected between baseline measurement level and the time interval between baseline measurement and death, with more adverse risk factor levels at baseline measurement times closer to the time of death. However, this was not found to be the case (data not shown), making it less likely that our findings were affected by sub-clinical disease. Importantly, we were able to confirm previously demonstrated relationships between cancer, CVD and baseline markers. As information on cancer deaths was obtained mainly from death certificates, Table 3 Hazard ratios (95% CI) for predictors of death from cancer, CVD or other causes
Cancer death (n = 94) P CVD death (n = 67) P Other deaths (n = 57) P In Cox proportional hazards modeling, the proportionality assumption was violated at P = 0.02 with the HDL/non-HDL cholesterol ratio as a predictor of death from CVD. By restricting follow-up time to >10 years, number of deaths was reduced by 9 and the proportionality assumption was no longer violated, but the hazard ratio ceased to be significantly different from 1 [HR 0.77 (95% CI 0.57, 1.04), P = 0.09].
misclassification of cause of death is possible. Nonetheless, autopsy studies show a high concordance rate between cancer pathology and death certificate cancer classification. 25 Being drawn from an occupational cohort of white males, our study sample was highly selected, but risk factor relationships are not necessarily generalizable, particularly with regard to cancer across different genders and ethnicities. 26 Prospective studies evaluating inflammatory biomarkers as predictors of cancer are almost exclusively restricted to CRP [27] [28] [29] [30] and WBC [10] [11] [12] [13] [14] and are not entirely consistent. It has been argued that WBC may only be associated with cancer mortality in smokers 10 but we found it predicted independently. In relation to cancer, ESR appears to have only been studied as a predictor of progression, 31, 32 although several studies have found it to predict incident CVD. 7, 8 To the best of our knowledge, no previous studies have examined globulin as a predictor either of cancer or CVD, although low albumin may predict CVD. 6 We found high globulin to be a markedly stronger predictor of both CVD and cancer than low albumin. We quantified the globulin fraction simply as the difference between total protein and albumin so, in relation to chronic disease, it may be the globulin fraction that is the active index and albumin levels vary inversely in order to maintain total protein concentrations. In support of this, a strong inverse relationship between the two fractions, measured independently, has been reported. 33 It remains unclear what distinguishes whether an individual will die of cancer or CVD. In our analysis, elevated cholesterol and BP were both risk factors for death from CVD, but their contribution was independent of inflammation. Whereas a global score of inflammation was strongly and similarly predictive of cancer and CVD mortality, some differences were apparent between individual inflammatory markers. WBC was particularly predictive of cancer mortality, in accord with potential mechanisms of carcinogenesis specific to activated leukocytes and macrophages, 34, 35 whereas ESR and globulin were more closely associated with CVD mortality. Early work on ESR identified plasma protein concentration as an important correlate, particularly with regard to globulin 36 and fibrinogen. 37 Overall, our results imply that inflammatory changes almost two decades previously play a determining role in death from chronic disease. Importantly, sub-clinical inflammation appeared to be as strong a predictor of cancer mortality as cigarette smoking and as strong a predictor of CVD mortality as serum cholesterol. The inflammation characteristics we distinguished can be detected with measurements that have been routinely available for many years and our findings imply that somewhat greater discrimination of risk status may be achieved by combining these in a single score.
